1. Despite the challenging business environment, Meghmani Organics Ltd. (MOL) revenue grew by 43.7% YoY to ₹ 640 Cr in Q3 FY22 aided by higher realisation from Pigments
along with improvement in volume & higher realisation from Agrochemicals business.
2. As an industry wide phenomenon, MOL too faced the challenge in respect to hardening of raw material prices.
Due to the sudden and sharp rise of raw material prices, MOL faced a challenge in terms of fully passing on to consumers.
3. EBITDA stood at ₹77.4 Cr with 12.1% EBITDA margins from 20.2% YoY
4. The 2-4D plant performed better amongst other products. The capacities are at par with Atul ltd after the earlier capex.
5. Impact of 1.5% on margins due to loss of incentive benefits from government
6. The prices of key raw materials are highly inflated for eg: Last year, industrial grade urea was costing ₹20, this year it has reached ₹75
7. Increase in commodity and other cost resulted in incremental pass on and thus overall agrochemical prices are elevated. As and when the input prices correct, expansion in margins will be visible.
8. Guidance of 40% growth in topline for FY22 from FY21 and to cross ₹3000 Cr in FY24
9. As the products in agrochemicals have increased from last year, contract manufacturing contribution went down from 25% to 20%
Segmental highlights
For 9MFY22, volume for agrochemicals grew by 40% and pigment has grown by 18%
Pigments business
1. The pigments contributed 32% of total revenues in Q3FY22
2. Volumes stood at 7281 MT with 88% capacity utilisation
3. EBITDA margins in the pigment business shrinked to 4.9% in Q3FY22 compared to 19.1% in Q3FY21
4. 82% of revenues in pigments were driven from exports
5. Improvement of margins in the pigment business in next one or two quarters is expected.
Agrochemical business
1. The agrochemical business contributed 68% to the topline
2. Volumes stood at 9428 MT with 74% capacity utilisation
3. EBITDA margins in the pigment business shrinked to 17.7% in Q3FY22 compared to 24.6% in Q3FY21
4. For agrochemical ,last year margins were exceptionally high because the raw material prices were too low and demand was high
5. Pyrethroids contribute almost 50% of revenues in agrochemicals business
6. Organo phosphates , neonicotinoid, are relatively much higher in toxicity and getting banned in certain regions.
Pyrethroid is relatively less toxic and being accepted in various markets
Competition in pyrethroid business is from UPL, Bayer, Heranba, Himani.
7. Majority of key products are backward integrated and two more backward integration products are underway
8. 35-40% business in the export business comes from MNC’s(FMC corp, Sumitomo, Adama, Newfarm)
Capex
1. The agrochemicals ongoing capex of ₹310 Cr is progressing as per the plan and commercial production is expected to begin in Q2FY23 with revenue potential of ₹600 Cr on full year of operations
2. During Q3 FY22, Meghmani Organics acquired Kilburn Chemicals Ltd. for ₹132 Cr, thereby fast-tracking its foray into Titanium Dioxide (TiO2) funded by internal accruals having 16,500 MTPA capacity
3. MOL anticipates doubling its Titanium Dioxide (TiO2) capacity to 33,000 MTPA by Q3 FY24 by incurring total capex of ₹600 Cr funded by an appropriate mix of internal accruals and debt.
4. Capex for the commercialisation of existing capacity in phase 1 will be ₹275 Cr(including acquisition cost) and completion by Q3FY23
5. The phase 2 for capacity expansion will incur the capex of ₹325 Cr and expected to commence production in Q3FY24
6. Post expansion and operations on yearly basis will generate ₹700- ₹750 Cr
7. Planning to sell majority of titanium dioxide products in domestic market
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1. The company’s performance for the quarter was affected by headwinds in the pharmaceutical business.
But was partly mitigated due to robust performance in the Contract Research and Development Services (CRDS) segment.
2. While the Radiopharma business showed improved performance, Generics business was affected by lower volumes due to Import Alert at Roorkee plant, latest sartan impurities issue and pricing pressure in the US generics market.
1. They have had a very strong quarter - especially in CRAMS where the pipeline continues to be very strong.
2. They are seeing good interest and strong growth in the Vitamin D analogues.
3. The cholesterol business is stable and the disinfectant business is seeing increased interest from customers.
4. They have seen a rapid rise in transportation and logistics costs. There are also price rises in Central Europe for basic utilities like electricity, gas and water.
1. Revenues stood at ₹475 Cr in Q3FY22 compared to ₹366 Cr in Q3FY21, growth of 29.4% YoY
2. EBITDA stood at 109.3 Cr translating 23% EBITDA margins
3. Sales volumes were down by 13.77% from 31,993 MT in Q3FY21 to 27,589 MT in Q3FY22. As few of the clients couldn’t procure Key Starting Materials (KSMs) to match the products.
4. Despite sluggish demand for few of the products and shut down of acetonitrile and DMF plants for debottlenecking which were completed in the month of November 2021, the revenues showed a decent growth of 44% which stood at ₹556 Cr in Q3FY22
1. Net revenues for the quarter were ₹348.6 Cr (4.6% growth YoY). EBITDA for the quarter stood at ₹73.4 Cr and EBITDA margin for the quarter was 21.1%.PAT for the quarter was ₹33 Cr and PAT margins were 9.5%.
2. Revenues from domestic formulation business for the quarter was ₹181.5 Cr (15.2% growth YoY). Major therapeutic segments viz. anti-infectives, gastrointestinal, urological and respiratory performed well.